News Releases

Patients Can Now Be Removed from Respiratory Isolation Following One or Two Negative Xpert MTB/RIF Results

Fourth Quarter Commercial Clinical Up 26% Driven by 29% Growth in Xpert® Reagents

Quantitative Test for Rapid Measurement of the HIV-1 Viral Load in Plasma Delivers Individual Results in About 90 Minutes

Accurate Norovirus Detection in as Little as One Hour

Redundant targets extend coverage for detection of seasonal and emerging novel viruses

With Funding from the Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation, Cepheid Expects to Deliver Prototype in as Little as Eight Weeks

Commercial Clinical Grows 23% Driven by 25% Growth in Xpert Tests

Acquires Customer Relationships from Former Distribution Partner

First molecular test indicated for samples from both males and females

Redundant targets extend coverage to provide detection of seasonal and emerging novel viruses

No Customer or Revenue Impact Expected

Program to Enable Broader Access to Groundbreaking Tuberculosis Diagnostic

Record HBDC Placements and Strength in North America Reagents Drive 27% Clinical Growth

Carbapenem Resistance Consortium Includes AstraZeneca, Cepheid, Cubist, and GSK

On-demand molecular test detects and differentiates the genes encoding the most prevalent carbapenemases: KPC, NDM, VIM, OXA-48 and IMP-1

Strong Commercial and HBDC Drive Clinical Growth of 26%

Accurate Norovirus Detection in as Short as One Hour

Xpert HPV is the Only Test Capable of Reporting High-risk Human Papillomavirus DNA in Captured Cervical Cells

Partnering to Increase Awareness About Tuberculosis, a Curable and Preventable Disease that Infects One-third of the World's Population

Custom Bike Designed by Paul Teutul Jr. to Lead the March Down Broadway to Highlight the Fight Against Tuberculosis in Honor of World TB Day

Record Commercial GeneXpert® System Placements and Strong Commercial Reagent Growth Highlight Building Momentum as Xpert® Test Menu Expands

First $100 Million Revenue Quarter Driven by Record Commercial Clinical and HBDC Sales

Revolutionary Tuberculosis Test Brings Accurate, Faster Results to Broader U.S. Market

Text RIDE to 50555 to Join our Mobile Community and Enter for a Chance to Win a Paul Jr. Designed Motorcycle

Campaign Aims to Raise TB Awareness and Funds to Fight Lung Disease

Revolutionary Tuberculosis Test Brings Accurate, Faster Results to U.S. Market

Record Revenue Driven by $18 Million Year-Over-Year Growth in Clinical

Record Revenue Highlights Strong Demand and Progress in Manufacturing, But Unanticipated Inventory Reserve Increases Costs

Test for Direct Identification of MRSA and Staphylococcus aureus from Positive Blood Cultures Includes Updates & Expanded Claims

Clinical Reagent Revenue Growth of 23% Driven by Continued Momentum of Xpert® Test Portfolio

Clinical Reagents Grow 32% in 2012

Xpert CT/NG Makes Same-Day Consultation and Treatment Possible for Two Most Common STDs

Preliminary Q4 2012 Revenue of Approximately $92 Million Reflects Stronger Than Expected Commercial Clinical Performance Offset By Lower HBDC

Rapid, On-Demand Results Deliver New Confidence in Same-Day Patient Consultation and Treatment

Xpert® Cartridge Backorders to Ship in October, Full Year Revenue Guidance Unchanged

CE-IVD Test Now Incorporates Lot-Specific Standardization Using WHO Standards

Industry's Highest Throughput System Capable of More Than 2,000 Daily Test Results

90-Minute On-Demand Results Deliver New Confidence in Same-Day Patient Consultation and Treatment

National Institutes of Health Awards $1.3 Million of Expected Five-Year, $5.5 Million Project

Record GeneXpert® System Placements Contribute to 39% Growth in Clinical Business

Record Revenue Driven by 33% Growth in Clinical Molecular Diagnostics

CE IVD Test Now Delivers Results Aligned to the International Scale

Redesigned GeneXpert Family Expands to Include Two-Module and Infinity-80 Systems

Record GeneXpert® System Placements Contribute to Record Revenue